item management s discussion and analysis of results of operations and financial condition results of operations o net revenues net revenues increased to million in from million in and million in  representing annual increases of and  respectively 
anatomic pathology net revenues increased to million in from million in  representing a increase  and increased from million in to million in  representing a increase 
the revenue growth reflects increased market penetration in the anatomic pathology area  including the impact of the kyto meridien diagnostics  llc kmd and pathologists reference laboratory prl acquisitions in may and february  respectively 
clinical chemistry net revenues decreased to million in from million in this decrease reflects the company s shift in emphasis toward anatomic pathology  and is a result of both volume and reimbursement reductions including medicare reimbursement pressures 
clinical chemistry net revenues increased million or from to this increase was primarily a result of the kmd acquisition 
o cost of sales cost of sales  which consists primarily of laboratory payroll and supplies  logistics and facility costs  increased to million in from million in and million in as a percentage of sales  cost of sales totaled  and in  and  respectively 
as a percentage of sales  cost of sales decreased from to  as a result of the operating leverage in the business and from the full integration of the kmd and prl acquisitions 
o gross profit gross profit totaled million in versus million in and million in  while gross profit margins were  and  respectively 
see item business reimbursement and regulatory matters  for a complete discussion of reimbursement and regulatory matters 
o selling  general and administrative expenses selling  general and administrative expenses increased to million in from million in and from million in these increases are primarily a result of increased commission expense  which is a result of increased revenues 
as a percentage of sales  selling  general and administrative expenses decreased significantly over the three year period from in to in  reflecting the operating leverage inherent in the business and from the full integration of the kmd and prl acquisitions 
o amortization of intangible assets amortization expense increased to  in from  in and from  in these increases are primarily a result of the kmd acquisition 
o research and development research and development expenses increased to million in from  in due to the continued development of the carepath tm program  a disease management information service for patients  physicians and managed care organizations 
research and development expenses remained flat between and at  and  respectively 
o income from operations income from operations increased to million in from million in and from million in these increases are due primarily to increased sales and cost control initiatives 
earnings before interest  taxes  depreciation and amortization ebitda increased to million in from million in as a percentage of sales  ebitda increased to in from in ebitda is defined as income before interest expense  income tax expense and depreciation and amortization 
non recurring items and gains and losses from sales of real estate and investments are also excluded from ebitda as these items do not impact operating results on a recurring basis 
the company had no such items for and management considers ebitda to be one measure of the cash flows from operations of the company before debt service that provides a relevant basis for comparison  and ebitda is presented to assist investors in analyzing the performance of the company 
this information should not be considered as an alternative to any measure of performance as promulgated under accounting principles generally accepted in the united states  nor should it be considered as an indicator of the overall financial performance of the company 
the company s calculation of ebitda may be different from the calculation used by other companies and  therefore  comparability may be limited 
ebitda for and are as follows ebitda   ebitda as a percentage of sales o net interest income net interest income increased to  in from  in due to the increased cash and cash equivalent position of the company over the period  resulting from cash generated by operations 
net interest income decreased to  in from  in primarily due to the funding of the acquisition of kmd in may o provision for income taxes the provision for income taxes increased to million in  from million in and million in  while the effective tax rate was  and  respectively 
the changes were due primarily to decreases in state tax rates 
o net income net income increased to million  from million in and million in basic earnings per share increased to per share in  from per share in and per share in diluted earnings per share increased to per share in  from per share in and per share in o liquidity and capital resources at december   the company had total cash and cash equivalents of million  substantially all of which was invested in a fund holding us treasury securities with maturities of less than three months 
working capital was million and million  as of december  and  respectively  and the current ratios were and  respectively 
accounts receivable totaled million and million  as of december  and  respectively  representing approximately days and days of average sales  respectively 
capital expenditures for and were million and million  respectively 
expenditures were primarily related to building expansion and information system enhancements 
in addition  million and  was expended in and for the acquisitions of kmd and prl  respectively 
effective february   the company entered into a three year  million line of credit agreement with a bank 
the agreement includes various provisions regarding borrowings under the facility  including financial and negative covenants 
in december  the loan was extended to august  and certain covenants were modified 
as of december   million was drawn down against this line 
the company s board of directors authorized the repurchase of approximately million shares of the company s common stock on the open market or in private transactions 
total expenditures for share repurchases is limited to million 
as of december   the company had repurchased approximately  shares of the company s common stock for approximately million 
effective february   the company acquired certain assets of a pathology laboratory in tampa  florida prl 
the acquisition price was approximately  including acquisition costs  of which  was paid through march  and the balance was satisfied through the assumption of certain liabilities 
the purchase price consisted primarily of trade receivables for  and customer lists for  and the acquisition has been accounted for pursuant to the purchase method of accounting 
effective may   the company acquired substantially all the assets of an outpatient ob gyn laboratory with locations in woodbury and new city  new york kmd 
the acquisition price was approximately million and was financed through a combination of available cash and drawdowns of the company s credit line  as well as through the issuance of common stock 
the purchase price was primarily allocated to customer lists million  goodwill million  lab and office equipment  and client receivables  partially offset by accrued liabilities 
the acquisition has been accounted for pursuant to the purchase method of accounting 
pro forma net revenues unaudited for the twelve months ended december  and  adjusted as if the acquisitions for kmd and prl had occurred january  and  respectively  approximate million and million respectively 
pro forma consolidated net income and earnings per share would not differ materially from the reported amounts 
effective october   the company acquired substantially all of the assets of john h 
altshuler  md  md  a pathology physician practice located in englewood  colorado  which specializes in dermatopathology and gyn pathology 
the acquisition price was approximately million and was financed through a combination of available cash and the issuance of common stock 
approximately  of the purchase price is being held in trust pursuant to a contingent earn out agreement 
the purchase price was primarily allocated to customer lists million  goodwill  lab and office equipment  and client receivables  partially offset by accrued liabilities of 
the acquisition has been accounted for pursuant to the purchase method of accounting 
pro forma consolidated net income and earnings per share  had the acquisition occurred january   would not differ materially from the reported amounts 
in the fourth quarter of  the company purchased preferred shares in and exclusive sales and distribution rights from response genetics  an applied genomic products and services company for an aggregate purchase price of million 
the company allocated the total investment to the distribution rights  and the preferred equity  based on management s estimations of future benefits from response genetics 
the company believes that cash flows from operations and available cash and cash equivalents are adequate to fund the company s operations for the foreseeable future 
risk factors  forward looking statements the management s discussion and analysis and the information provided elsewhere in this annual report on form k contain forward looking statements regarding the company s future plans  objectives  and expected performance 
these statements are based on assumptions that the company believes are reasonable  but are subject to a wide range of risks and uncertainties  and a number of factors could cause the company s actual results to differ materially from those expressed in the forward looking statements referred to above 
these factors include  among others  the uncertainties in reimbursement rates and reimbursement coverage of various tests sold by the company to beneficiaries of the medicare program see eg  item business reimbursement  being deemed to be not in compliance with federal or state regulatory requirements see eg  item business regulatory  the uncertainties relating to the ability of the company to convince physicians and or managed care organizations to use the company as a provider of anatomic pathology testing services  the ability of the company to maintain superior quality relative to its competitors  the ability of the company to maintain its hospital based business in light of the competitive pressures and changes occurring in hospital healthcare delivery  the uncertainties relating to states erecting barriers to the performance of anatomic pathology testing by out of state laboratories  the ability of the company to find  attract and retain qualified management and technical personnel  the uncertainties associated with competitive pressures from the large national laboratories  small specialized laboratories and well established local pathologists  and the uncertainties which would arise if integrated delivery systems closed to outside providers emerged as the dominant form of health care delivery 
item a 
quantitative and qualitative disclosures about market risk none 
